DesiNew – Daily Breaking News and Updates

Scientists have developed a new respiratory delivery system for vaccines

NEW YORK: Scientists have developed a respiratory delivery system for a vaccine that produces immune-responsive genes in mice and non-human primates without damaging the lungs, a precursor to which is similar to covid-19. New treatments for respiratory diseases can lead to treatment.
The findings, published in the journal Med, suggest that a safe and effective system could be developed for the supply of lungs and vaccines against pathogens such as the novel corona virus.
“This translation strategy enables potentially more effective delivery of treatments and vaccines while reducing the likelihood of toxic side effects,” said Wadia Arap, co-author of the study at the Rutgers Cancer Institute in the United States.
According to the researchers, this method of vaccine delivery has many advantages over other routes, especially for the development of vaccines against respiratory infections as the treatment reaches the site of infection directly.
He said that it is especially attractive for the management of various foods.
The researchers said that this method improves the bio-presence and reduces the possible side effects by achieving a faster start.
Scientists believe that airborne pathogens can protect against airborne pathogens that cause diseases such as tuberculosis, influenza, Ebola, measles and colic 19
However, he said that this approach has not been widely adopted, partly because the basic physical mechanisms are largely unknown.
He said it is important to answer this question in order to design a general use of the general lung supply system.
In a new study, researchers designed and demonstrated a safe and efficient delivery system to the lungs.
He said the approach involves the use of phased viruses that can cause infections and replication in bacterial cells.
In some types of vaccines, he said, phase particles that carry small proteins, or peptides, are used to stimulate the immune response.
First, the researchers tested a small protein key and identified it – the cake MMSDC – which can effectively deliver phase particles across the pulmonary barrier and into the bloodstream.
They found that the inhaled supply of phage particles exhibiting cake MMSLDC showed a strong antibody response against phage particles in mice and non-human primates without damaging the lungs.
According to scientists, the new system of lung supply is safe and effective, and there are unique benefits to the development of vaccines and therapies against airborne pathogens.
He said that phage particles have a very strong and permanent immune response without causing toxic side effects.
Because they do not replicate inside eukaryotic cells, their use is generally considered safer than other classic viral vaccination strategies.
In terms of practical application, the study found that phage particles are extremely stable in harsh environmental conditions, and their mass production is highly cost-effective compared to traditional methods used to make vaccines.
Scientists say that unlike traditional vaccines that are often inactive, the new lung supply system does not require a cumbersome, hard or expensive cold chain for field application in the developing world.
“In addition, phase particles are versatile and can be genetically engineered using standard molecular biology technology,” Arap said.
The researchers plan to examine the dynamics of pulmonary transport after multiple doses next time and investigate the cell-based immune response.


Exit mobile version